Description
Join GRAIL for an exciting conversation about advancements in multi-cancer early detection. We will provide updates on our clinical validation program, including positive top-line performance and safety results from the PATHFINDER 2 trial, as well as review the latest efforts to establish timely, equitable access with policymakers.
This briefing is not intended for members of the media. If you are a member of the press, we kindly ask that you contact our communications team.